The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. In
some patients with NAFLD, isolated steatosis can progress to advanced stages with non …

Background Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease worldwide. The increasing prevalence of NAFLD mirrors that of obesity and type 2 …

Non‐alcoholic fatty liver disease (NAFLD) has a rapidly rising prevalence worldwide and is
the most common cause of liver disease in developed countries. In this article, we discuss …

Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients with diabetes
mellitus and increasing evidence suggests that patients with type 2 diabetes are at a …

In the recent years, non-alcoholic fatty liver disease (NAFLD) has emerged as the
commonest cause of chronic liver disease in the developed world. The global epidemic of …

Non-alcoholic fatty liver disease (NAFLD) is now the most frequent chronic liver disease that
occurs across all age groups and is recognized to occur in 14%-30% of the general …

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in Western
countries. It encompasses a wide spectrum of liver lesions, from pure steatosis to end-stage …

Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-
associated steatotic liver disease (MASLD) affects~ 70% of patients with type 2 diabetes …

Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) frequently
coexist as they share the pathogenic abnormalities of excess adiposity and insulin …

This review summarizes our current understanding of nonalcoholic fatty liver disease
(NAFLD), a multi-factorial systemic disease resulting from a complex interaction between a …